Eiger BioPharmaceuticals Announces Bankruptcy and Liquidation Plan
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) acquired avexitide from Eiger BioPharmaceuticals Inc (OTC:EIGRQ) for $35.1 million.Avexitide is an investigational, first-in-class glucagon-like peptide-1 (
Amylyx Jumps on Acquisition of Eiger's GLP-1 Drug
Express News | Amylyx Pharmaceuticals Shares Are Trading Higher After the Company Announced That It Acquired Avexitide From Eiger BioPharmaceuticals
Express News | Eiger BioPharmaceuticals Inc - Sale of Co's Avexitide Asset Closed on July 9
Express News | Eiger BioPharmaceuticals Inc - at Hearing Held on June 26, Bankruptcy Court Approved Sale of Co's Avexitide Asset to Amylyx
Amylyx Pharmaceuticals: Expect to Begin the Phase 3 Program for Avexitide in PBH in 1Q 2025 >AMLX
Amylyx Pharmaceuticals: Expect to Begin the Phase 3 Program for Avexitide in PBH in 1Q 2025 >
Amylyx Pharmaceuticals Acquires Avexitide From Eiger BioPharmaceuticals >AMLX
Amylyx Pharmaceuticals Acquires Avexitide From Eiger BioPharmaceuticals >
Eiger BioPharmaceuticals Issues Cautionary Chapter 11 Reports
Amylyx Inks Deal to Buy Eiger's GLP-1 Targeting Drug
Express News | Eiger BioPharmaceuticals Inc - Asset Purchase Agreement for $35.1 Million, Plus Aggregate Amount of Determined Cure Costs and Assumed Liabilities
Express News | Eiger BioPharmaceuticals Inc - Company and Amylyx Entered Into an Asset Purchase Agreement
Express News | Spruce Biosciences- Agreed to Buy All Rights,Title,Interests in,to & Under Some Assets,Interests Used by Eiger BioPharmaceuticals Related to Avexitide
Eiger BioPharmaceuticals Cautions Investors Amid Bankruptcy
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug
Sentynl Therapeutics, a US-based biopharmaceutical subsidiary of Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321), completed the acquisition of the proprietary rights to Eiger BioPharmaceuticals' Zokinv
Express News | Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome From Eiger BioPharmaceuticals
Eiger Biopharmaceuticals CFO Exits Amid Bankruptcy Reorganization
Express News | Eiger BioPharmaceuticals- on April 26, William G. Kachioff Notified Co of His Resignation as Co’s Chief Financial Officer
News On Eiger BioPharmaceuticals Inc. (EIGR) Now Under EIGRQ
News On Eiger BioPharmaceuticals Inc. (EIGR) Now Under EIGRQ
ATOS, SMR and EIGR Are Among Pre Market Gainers
No Data